Advancing in vivo CAR-T therapies just got a $50.0M boost for Vivacta Biotechnology, which has closed its Series A funding round. The biotech firm secured the capital from a syndicate of investors including Loyal Valley Capital, Decheng Capital, and OrbiMed.
Vivacta, dedicated to its specialized focus on in vivo CAR-T therapies, was originally spun out from global leading investors, providing a robust foundation for its therapeutic development.














